Outcomes and Associated Factors of Cervical Human Papillomavirus Infection Among 608 Women in Shenzhen, China, 2018-2023

Overview

Journal Front Public Health

Date 2025 Jan 29

PMID 39877908

Authors

Zhenghan Lv

Xuesen He

Zhiju Li

Yue Yuan

Xinyi Zhou

Changqing Tu

Yinqi Yang

Yanshan Huang

Lili Yin

Huihui Chen

Yanling Tao

Affiliations

Soon will be listed here.

Abstract

Objective: This study aimed to uncover the patterns of Human papillomavirus (HPV) infection outcomes in women and assess the risk factors that may affect these outcomes.

Methods: A retrospective study was conducted on 608 women who tested positive for HPV-DNA during their initial visit to the outpatient department of Shenzhen Longgang Central Hospital from 2018 to 2023 and who had subsequent HPV-DNA testing as part of their post-visit monitoring. The monitoring intervals were every 6 months. The rank sum test was used to analyze ranked data. The Kaplan-Meier method was used to analyze the turning negative time. Univariate analysis was performed using the log-rank test, and multivariate analysis was performed using the Cox model to analyze independent risk factors.

Results: The results showed that the median age was 40.00 years (interquartile 33.00-47.00 years), the total conversion rate of the HPV-negative patients was 38.98%, and the median conversion time of the HPV-negative patients was 8.95 months (interquartile 4.20-16.175 months). Age, infection status and type of health insurance were significantly correlated with HPV outcome ( < 0.05).

Conclusion: Among women infected with HPV, the overall rate of negative HPV infection was 38.93%, and the duration of negative conversion was 8.95 months. The study revealed that age, HPV infection status, and type of medical insurance are independent predictors of the persistence of negative HPV test outcomes.

References

He C, Song C, Li M, Ma W, Sun S . Meta-analysis of the effect and safety of recombinant human interferon α-2b combined with Baofukang suppository in the treatment of HPV infection. Am J Transl Res. 2022; 14(11):7632-7642. PMC: 9730096. View

Duan R, Xu K, Huang L, Yuan M, Wang H, Qiao Y . Temporal Trends and Projection of Cancer Attributable to Human Papillomavirus Infection in China, 2007-2030. Cancer Epidemiol Biomarkers Prev. 2022; 31(5):1130-1136. DOI: 10.1158/1055-9965.EPI-21-1124. View

Mollers M, King A, Knol M, Scherpenisse M, Meijer C, van der Klis F . Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study. Vaccine. 2015; 33(23):2678-83. DOI: 10.1016/j.vaccine.2015.04.016. View

Rosano A, Dauvrin M, Buttigieg S, Ronda E, Tafforeau J, Dias S . Migrant's access to preventive health services in five EU countries. BMC Health Serv Res. 2017; 17(1):588. PMC: 5568253. DOI: 10.1186/s12913-017-2549-9. View

Ni X, Hu J, Huang Y, Tao J, Zhu H . Higher clearance rates of multiple HPV infections may explain their lower risk of HSIL: A retrospective study in Wenzhou, China. J Med Virol. 2023; 95(2):e28526. DOI: 10.1002/jmv.28526. View

Zhao F, Lewkowitz A, Hu S, Chen F, Li L, Zhang Q . Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012; 131(12):2929-38. PMC: 3435460. DOI: 10.1002/ijc.27571. View

Li N, Hang D, Yang L, Feng X, Lyu Z, Xie S . Persistence of type-specific human papillomavirus infection among Daqing City women in China with normal cytology: a pilot prospective study. Oncotarget. 2017; 8(46):81455-81461. PMC: 5655299. DOI: 10.18632/oncotarget.20188. View

Zhang S, Xu H, Zhang L, Qiao Y . Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2021; 32(6):720-728. PMC: 7797226. DOI: 10.21147/j.issn.1000-9604.2020.06.05. View

Luo Q, Zeng X, Luo H, Pan L, Huang Y, Zhang H . Epidemiologic characteristics of high-risk HPV and the correlation between multiple infections and cervical lesions. BMC Infect Dis. 2023; 23(1):667. PMC: 10560423. DOI: 10.1186/s12879-023-08634-w. View

10.

Zhu B, Liu Y, Zuo T, Cui X, Li M, Zhang J . The prevalence, trends, and geographical distribution of human papillomavirus infection in China: The pooled analysis of 1.7 million women. Cancer Med. 2019; 8(11):5373-5385. PMC: 6718589. DOI: 10.1002/cam4.2017. View

11.

Dang Y, Zou G, Peng B, Ling L . Health Service Seeking Behavior among Migrant Workers in Small and Medium-Sized Enterprises in Guangdong, China: Does Family Migration Matter?. Biomed Res Int. 2019; 2018:3620436. PMC: 6288583. DOI: 10.1155/2018/3620436. View

12.

Bogani G, Pinelli C, Chiappa V, Martinelli F, Lopez S, Ditto A . Age-specific predictors of cervical dysplasia recurrence after primary conization: analysis of 3,212 women. J Gynecol Oncol. 2020; 31(5):e60. PMC: 7440983. DOI: 10.3802/jgo.2020.31.e60. View

13.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

14.

Louvanto K, Syrjanen K, Rintala M, Grenman S, Syrjanen S . Genotype-specific clearance of genital human papillomavirus (HPV) infections among mothers in the Finnish family HPV study. J Clin Microbiol. 2010; 48(8):2665-71. PMC: 2916623. DOI: 10.1128/JCM.00783-10. View

15.

Campari C, Fedato C, Iossa A, Petrelli A, Zorzi M, Anghinoni E . Cervical cancer screening in immigrant women in Italy: a survey on participation, cytology and histology results. Eur J Cancer Prev. 2015; 25(4):321-8. DOI: 10.1097/CEJ.0000000000000173. View

16.

van Eer K, Middeldorp M, Dzebisasjvili T, Lamkaraf N, de Melker H, Steenbergen R . Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women. J Infect Dis. 2023; 228(8):1012-1022. DOI: 10.1093/infdis/jiad080. View

17.

Hertzum-Larsen R, Kjaer S, Frederiksen K, Thomsen L . Participation in cervical cancer screening among immigrants and Danish-born women in Denmark. Prev Med. 2019; 123:55-64. DOI: 10.1016/j.ypmed.2019.02.023. View

18.

Calvo-Torres J, Rejas J, Ramirez-Mena M, Gonzalez-Granados C, Bradbury M, Del Pino M . Menopause in adult women with human papillomavirus: health-related quality of life and determinants. Menopause. 2024; 31(9):809-817. DOI: 10.1097/GME.0000000000002395. View

19.

Liu R, He X, Bao W, Li Z . Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review. Hum Vaccin Immunother. 2024; 20(1):2396710. PMC: 11364057. DOI: 10.1080/21645515.2024.2396710. View

20.

Westrich J, Warren C, Pyeon D . Evasion of host immune defenses by human papillomavirus. Virus Res. 2016; 231:21-33. PMC: 5325784. DOI: 10.1016/j.virusres.2016.11.023. View